Fusion Antibodies PLC
LSE:FAB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.8
19.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
Fusion Antibodies PLC
LSE:FAB
|
15.3m GBP |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
237.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
166.8B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
83.6T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.4B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.1B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
277.8B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.3B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.9B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
20.2B EUR |
Loading...
|
Market Distribution
| Min | -195 650% |
| 30th Percentile | 0% |
| Median | 0.1% |
| 70th Percentile | 0.2% |
| Max | 4 630.7% |
Other Profitability Ratios
Fusion Antibodies PLC
Glance View
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Fusion Antibodies PLC is -95.6%, which is above its 3-year median of -128.3%.
Over the last 3 years, Fusion Antibodies PLC’s Operating Margin has decreased from -45.8% to -95.6%. During this period, it reached a low of -201.4% on Mar 31, 2024 and a high of -45.8% on Aug 30, 2022.